Infigratinib Shows Promising Early Activity in FGFR2-Altered Cholangiocarcinoma
- This topic has 0 replies, 1 voice, and was last updated 2 years, 8 months ago by
.
Viewing 1 post (of 1 total)
-
Posts
-
Infigratinib Shows Promising Early Activity in FGFR2-Altered Cholangiocarcinoma
The FGFR inhibitor infigratinib demonstrated promising clinical activity and a manageable safety profile in previously treated patients with locally advanced or metastatic cholangiocarcinoma whose tumors harbor FGFR2 gene fusions or rearrangement.
Thanks to OncLive for this piece.
Gavin
Viewing 1 post (of 1 total)
- The forum ‘Chemotherapy & More’ is closed to new topics and replies.